![]() In addition, on today's conference call, non-GAAP financial measures will be used. You are cautioned not to place undue reliance on these forward-looking statements and Horizon disclaims any obligation to update such statements. ![]() Our actual results could differ materially from these forward-looking statements due to a number of factors, including the risk factors and other information outlined in our latest Forms 10-K, 10-Q and any 8-Ks filed with the Securities and Exchange Commission, and our earnings press release, which we issued this morning. We posted our investor slide deck this morning as well.ĭuring today's call, we will be making certain forward-looking statements, including statements about financial projections, development activities, our business strategy and the expected timing and impact of future events. After closing remarks from Tim, we will take your questions. Liz will then review our R&D programs, followed by Aaron, who will discuss our financial performance and guidance in more detail. ![]() Tim will provide a review of the business, including our second-quarter performance and our revised full-year guidance. On the call with me today are Tim Walbert, Chairman, President and Chief Executive Officer Liz Thompson, Executive Vice President, Research and Development Aaron Cox, Executive Vice President, Chief Financial Officer and Andy Pasternak, Executive Vice President, Chief Strategy Officer. Good morning, everyone, and thank you for joining us. Tina Ventura, Senior Vice President and Chief Investor Relations Officer. As a reminder, today's conference call is being recorded. Welcome to the Horizon Therapeutics plc Second Quarter 2022 Earnings Conference Call. Good morning and thank you for standing by. Tim Walbert - Chairman, President and Chief Executive OfficerĮlizabeth Thompson - Executive Vice President, Research & DevelopmentĪaron Cox - Executive Vice President and Chief Financial OfficerĪndy Pasternak - Executive Vice President, Chief Strategy OfficerĪnnabel Samimy - Stifel, Nicolaus & Company, Inc. Tina Ventura - Senior Vice President, Chief Investor Relations Officer PROCYSBI (cysteamine bitartrate) delayed-release capsules and delayed-release oral granules is a prescription medicine used to treat nephropathic cystinosis in adults and children 1 year of age and older.Horizon Therapeutics Public Limited Company ( NASDAQ: HZNP) Q2 2022 Results Earnings Conference Call Aug8:00 AM ET BUPHENYL (sodium phenylbutyrate) is a tablet for oral administration and BUPHENYL (sodium phenylbutyrate) Powder for oral, nasogastric, or gastrostomy tube administration contains sodium phenylbutyrate. ACTIMMUNE is part of a drug regimen used to treat Chronic Granulomatous Disease (CGD). The Company’s portfolio of medicines include ACTIMMUNE, BUPHENYL (sodium phenylbutyrate), KRYSTEXXA pegloticase, PROCYSBI (cysteamine bitartrate), Prescription RAVICTI (glycerol phenylbutyrate), TEPEZZA teprotumumab-trbw and other. The Company is focused on the discovery, development and commercialization of medicines that address the critical needs of people impacted by rare, autoimmune and severe inflammatory diseases. ![]() Horizon Therapeutics plc is an Ireland-based global biotechnology company.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |